Wegovy vs Mounjaro: Differences, Effectiveness, and Which Is Better

Head-to-head data from the SURMOUNT-5 trial showed tirzepatide producing an average of about 20 percent body weight loss versus roughly 14 percent for semaglutide over 72 weeks — the first large direct clinical comparison of the two most talked-about medicines in the GLP-1 era. The Wegovy vs Mounjaro decision, however, involves far more than a single weight-loss number. The two drugs have different FDA indications, different mechanisms, different side-effect profiles, different pricing, and different insurance coverage patterns — and, importantly, they are not even approved for the same use. This guide walks through what actually separates them and how to think about which makes sense for your situation. It is general education, not medical advice; the choice between these drugs belongs to a licensed clinician who knows your history. Start with our medical conditions guide for context.

First, Are They Actually Comparable Drugs?

Technically, Wegovy and Mounjaro are not directly comparable, because they are approved for different indications. Wegovy (semaglutide 2.4 mg weekly) is FDA-approved for chronic weight management in adults with obesity, or overweight with a weight-related condition, alongside diet and exercise. In eligible adults who also have established cardiovascular disease and are overweight or obese, Wegovy is additionally approved to reduce the risk of major cardiovascular events such as heart attack and stroke. Mounjaro (tirzepatide) is FDA-approved for improving blood sugar in adults with type 2 diabetes. The apples-to-apples weight-loss comparison of the underlying molecules is Wegovy versus Zepbound, which contains the same tirzepatide as Mounjaro but is the product FDA-approved for chronic weight management (and, per current FDA labeling, for moderate-to-severe obstructive sleep apnea in adults with obesity — verify the exact product and indication with your clinician).

In practice, patients and prescribers often line Wegovy and Mounjaro up side by side because both are widely used and because the underlying molecules — semaglutide and tirzepatide — are the two leaders in this class. When people say “Wegovy vs Mounjaro,” they usually mean the broader semaglutide-vs-tirzepatide question. Just be clear on one point the FDA labeling makes: Mounjaro itself is not approved for weight loss. Using Mounjaro purely for weight loss is off-label; Zepbound is the on-label tirzepatide choice for that goal. For the on-label comparison, see our Zepbound for weight loss guide.

Mechanism Differences

Wegovy contains semaglutide, which activates the glucagon-like peptide-1 (GLP-1) receptor. When activated, GLP-1 signaling slows gastric emptying, reduces appetite through brain pathways, and enhances glucose-dependent insulin secretion. Semaglutide is a single-agonist drug hitting just the GLP-1 receptor. (The same molecule is sold as Ozempic and Rybelsus for type 2 diabetes, and semaglutide has additional FDA-approved uses, including reducing kidney-disease risk in some patients and treating a form of metabolic liver disease — a reminder that “semaglutide” is a family of products with different labels.)

Mounjaro contains tirzepatide, which activates two hormone receptors at once: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). GIP works alongside GLP-1 to influence glucose metabolism and appetite, and its co-activation appears to add to the weight-loss effect. This dual mechanism is the leading explanation for why tirzepatide edges out semaglutide on pure weight-loss outcomes in the trial data. Both are classed as “incretin mimetics,” and both are given as a once-weekly injection.

Weight Loss: SURMOUNT-5 and Other Data

The SURMOUNT-5 head-to-head trial enrolled adults with obesity and without diabetes and randomized them to maximum-tolerated-dose tirzepatide or maximum-tolerated-dose semaglutide over 72 weeks. Tirzepatide produced an average weight loss of about 20 percent compared with roughly 14 percent for semaglutide — a statistically significant advantage of several percentage points for tirzepatide. These are trial averages, not guarantees: individual results vary widely, and some people lose more on semaglutide than the average person loses on tirzepatide.

These findings line up with what indirect comparisons across the STEP and SURMOUNT programs already suggested. STEP-1 showed semaglutide 2.4 mg producing roughly 15 percent weight loss over 68 weeks. SURMOUNT-1 showed the top tirzepatide dose producing in the low-20-percent range over 72 weeks. Across both direct and indirect data, tirzepatide tends to outperform semaglutide on average weight loss in the obesity population — while both dramatically outperform anything available before this class arrived. Weight regain after stopping either drug is common, which is why clinicians frame these as long-term treatments for a chronic condition rather than short courses.

Side Effect Profiles

Both drugs share the common GLP-1 class side effects: nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, and indigestion. Nausea is most common during titration on either drug and typically eases over weeks as tolerance develops. Injection-site reactions are possible but uncommon with either.

Published data and real-world experience suggest tirzepatide’s gastrointestinal effects may be somewhat more intense on average at the highest doses, plausibly because the absolute weight loss is greater. Both carry the same boxed warning for thyroid C-cell tumors, including medullary thyroid carcinoma, based on rodent studies; the human risk is not established, but both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Report neck lumps, hoarseness, trouble swallowing, or persistent shortness of breath. Rare but serious risks for both include pancreatitis, gallbladder disease, and acute kidney injury from severe dehydration; severe, persistent stomach pain warrants prompt medical care. Tirzepatide may also make oral hormonal contraceptives less effective for a period after starting or changing the dose, so discuss backup contraception with your clinician. For details see our tirzepatide side effects article.

Dosing and Titration (Prescriber-Directed)

Both drugs are started low and increased slowly to limit side effects, and the exact schedule is individualized by your prescriber. The information below describes how titration generally works; it is not a self-dosing plan. Wegovy is designed to step up gradually over several months to its 2.4 mg weekly maintenance dose, given once weekly by injection in the abdomen, thigh, or upper arm. Mounjaro likewise starts low and steps up on a monthly cadence as tolerated toward higher weekly doses, though many patients settle at an intermediate maintenance dose rather than the maximum.

Never accelerate a titration, “make up” a missed dose by doubling, or copy a schedule from the internet — dosing errors are a documented source of harm, especially with non-standard products. If side effects are rough, your clinician can hold a dose or slow the increase. For dose schedules see our Wegovy doses article.

Cost and Insurance Coverage

Prices and coverage for these drugs change frequently, so treat every figure here as an estimate to verify with the pharmacy, manufacturer, and your plan. At list (wholesale acquisition) prices, both sit near the top of the retail drug market — Wegovy has listed on the order of roughly $1,300+ per month and Mounjaro somewhat lower, in the neighborhood of about $1,000+ per month, though what anyone actually pays depends heavily on coverage and programs. Commercial insurance coverage for Wegovy is generally tied to weight-management (and, increasingly, cardiovascular) indications, while Mounjaro coverage is generally tied to type 2 diabetes.

Both manufacturers offer savings and self-pay options that can lower costs substantially for eligible people. Novo Nordisk’s programs (including NovoCare self-pay) and Eli Lilly’s programs (including LillyDirect) have offered cash-pay pricing and copay assistance for eligible commercially insured patients, with the specifics and dollar amounts changing over time. Manufacturer copay cards generally do not apply to Medicare, Medicaid, or other federal beneficiaries. Confirm current cash prices, copay floors, and eligibility directly with the manufacturer before you count on any number. See our Wegovy cost guide and Mounjaro price breakdown.

A Word on Compounded and Gray-Market GLP-1 Products

During the 2022–2024 shortages, compounded semaglutide and tirzepatide became widely available. The FDA has since declared those shortages resolved, and the large-scale compounding that the shortage allowed has been winding down. The FDA warns that unapproved, compounded, counterfeit, or “for research purposes only” GLP-1 products have not been reviewed for safety, effectiveness, or quality, and it has documented dosing errors requiring hospitalization, products arriving warm or improperly stored, and counterfeits with false labeling or the wrong ingredients. Retatrutide and cagrilintide, sometimes marketed online, are not FDA-approved for any use. The safest path is an FDA-approved product obtained through a legitimate pharmacy with a clinician’s prescription — not a syringe and a vial from a website.

Which Drug for Which Patient

For a patient with type 2 diabetes seeking glucose control plus some weight loss, Mounjaro is the on-label choice and typically produces strong A1C reduction along with meaningful weight loss. For a patient with obesity and no diabetes seeking weight loss, Wegovy is an on-label option — with Zepbound (the same tirzepatide as Mounjaro) as the on-label tirzepatide alternative that produces greater average weight loss in trials. For a patient who already has heart disease and qualifies, Wegovy’s cardiovascular indication may tip the balance.

In the real world, prescribers often choose based on what a patient’s insurance actually covers, prior tolerability with GLP-1 drugs, other medical conditions, and individual response. Someone who struggled with semaglutide side effects may do fine on tirzepatide (or vice versa), and switching between the two is clinically common. None of this is a decision to make alone from a blog.

Frequently Asked Questions

Which loses more weight, Wegovy or Mounjaro?

In the direct SURMOUNT-5 comparison, tirzepatide (the molecule in Mounjaro and Zepbound) produced greater average weight loss than semaglutide (Wegovy) over 72 weeks — roughly 20 percent versus about 14 percent. Individual results vary widely, and averages do not predict any one person’s outcome.

Is Mounjaro FDA-approved for weight loss?

No. Mounjaro is FDA-approved for type 2 diabetes. Zepbound, which contains the same tirzepatide, is the FDA-approved product for chronic weight management (and, per current labeling, for moderate-to-severe obstructive sleep apnea in adults with obesity). Using Mounjaro specifically for weight loss is off-label.

Can you switch from Wegovy to Mounjaro?

Clinicians commonly switch patients between these drugs based on insurance coverage, side effects, or inadequate response. The switch is a prescriber’s decision, and the new drug is generally restarted at a low dose regardless of your prior dose, to let tolerance rebuild. Do not switch or overlap medicines on your own.

Do Wegovy and Mounjaro have the same side effects?

They share the same core gastrointestinal profile — nausea, vomiting, diarrhea, constipation, and abdominal pain — though tirzepatide may be somewhat more intense on average at maximum doses. Both carry the same boxed warning for thyroid C-cell tumors and the same rare risks such as pancreatitis and gallbladder problems.

Which is cheaper, Wegovy or Mounjaro?

At list prices, Mounjaro has generally been somewhat cheaper than Wegovy, but list price rarely reflects what people pay. Actual out-of-pocket cost depends on insurance coverage and manufacturer self-pay or copay programs, which change often and favor different patients for each drug. Verify current pricing directly with the manufacturer and your plan.

Are compounded versions a safe way to save money?

The FDA has warned about unapproved, compounded, and counterfeit GLP-1 products, including dosing errors and fake products. With the shortages resolved, the safest option is an FDA-approved product from a legitimate pharmacy. Discuss affordable, legitimate options with your prescriber rather than buying from gray-market sellers.

The Bottom Line on Wegovy vs Mounjaro

For maximum average weight loss, tirzepatide-based drugs (Mounjaro for diabetes, Zepbound for weight loss) tend to outperform semaglutide-based drugs (Ozempic for diabetes, Wegovy for weight loss) in head-to-head data. But FDA indications, insurance coverage, other health conditions, side-effect tolerance, and individual response often matter more than a few percentage points of average weight loss. Many patients do very well on Wegovy; others respond better to tirzepatide. Work with your prescriber to match the drug — and the indication — to your specific situation, use only FDA-approved products from legitimate pharmacies, and don’t hesitate to revisit the plan if your first choice isn’t working. Both drugs represent major progress over anything available before this class arrived.

Sources

• MedlinePlus (U.S. National Library of Medicine) — Semaglutide Injection; Tirzepatide Injection
• U.S. Food and Drug Administration — prescribing information for Wegovy, Mounjaro, and Zepbound; drug-safety statements on unapproved, compounded, and counterfeit GLP-1 drugs used for weight loss
• New England Journal of Medicine — SURMOUNT-5 (tirzepatide vs semaglutide head-to-head trial)
• New England Journal of Medicine — STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) trials
• Novo Nordisk / NovoCare and Eli Lilly / LillyDirect — manufacturer product and pricing information (verify current figures)